Filing Details

Accession Number:
0001179110-15-016421
Form Type:
4
Zero Holdings:
No
Publication Time:
2015-12-17 15:40:57
Reporting Period:
2015-12-15
Filing Date:
2015-12-17
Accepted Time:
2015-12-17 15:40:57
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
882095 Gilead Sciences Inc GILD Biological Products, (No Disgnostic Substances) (2836) 943047598
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1190273 W Norbert Bischofberger Gilead Sciences, Inc.
333 Lakeside Drive
Foster City CA 94404
Evp, R&d And Cso No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2015-12-15 43,600 $23.76 171,536 No 4 M Direct
Common Stock Acquisiton 2015-12-15 26,400 $19.09 197,936 No 4 M Direct
Common Stock Disposition 2015-12-15 30,431 $102.66 167,505 No 4 S Direct
Common Stock Disposition 2015-12-15 39,569 $102.22 127,936 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Non-Qualified Stock Option (right to buy) Disposition 2015-12-15 26,400 $0.00 26,400 $19.09
Common Stock Non-Qualified Stock Option (right to buy) Disposition 2015-12-15 43,600 $0.00 43,600 $23.76
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
211,600 2021-01-20 No 4 M Direct
28,800 2020-01-28 No 4 M Direct
Footnotes
  1. The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan.
  2. The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested.
  3. Sale prices reported for the transactions reported here range from $101.46 to $102.45. Full information regarding the number of shares purchased or sold at each separate p2rice will be provided to the SEC, the issuer or its shareowners upon request
  4. Sale prices reported for the transactions reported here range from $102.46 to $102.99. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.
  5. The options have a four year vesting schedule. 25% of the options will vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.